Market cap
$7 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -69.05 | -61.83 | -2.96 | -42.83 | 0.04 |
| EBIT | -10.73 | -10.38 | 14.11 | -1.99 | -6.41 |
| Net Profit | 85.63 | -304.53 | -409.22 | -206.85 | -210.52 |
| EPS | 55.08 | -1,572.96 | -124.22 | 7.53 | 11.22 |
| Book Value | -- | -- | 558.76 | -47.01 | -31.34 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Sep-25 | Sep-24 | Sep-23 |
| EBIT-Margin
| -245.33 | -176.58 | -- | -408.72 | -81.94 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -488.13 | -344.92 | -1,253.80 | -99.23 | -111.37 |
| Return on Capital
| -449.23 | -316.92 | -1,156.52 | -87.02 | -104.15 |
| Return on Assets
| -305.01 | -217.04 | -806.75 | -52.89 | -55.39 |
| Debt to Equity (x)
| -- | -- | 0.10 | 0.08 | 0.25 |
Profitability
ROCE
-1,156.52
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-1,156.52
|
-87.02
|
-104.15
|
-69.74
|
-167.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-1,253.80
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-1,253.80
|
-99.23
|
-111.37
|
-69.74
|
-190.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-806.75
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-806.75
|
-52.89
|
-55.39
|
-45.68
|
-124.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
--
|
-408.72
|
-81.94
|
-76.89
|
-138.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-3,251.74
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-3,251.74
|
-203.78
|
-74.41
|
-46.11
|
-177.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-0.38
--
Year on year growth in net sales
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-0.38
|
-0.74
|
-0.26
|
1.01
|
3.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
--
|
-28.04
|
21.59
|
-11.52
|
0.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-893.74
--
Year on year growth in profit after tax
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-893.74
|
29.70
|
-18.73
|
47.73
|
-25.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-307.24
--
Year on year growth in earnings per share
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-307.24
|
0.97
|
0.01
|
0.65
|
0.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.10
--
Total debt / Net worth
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
0.10
|
0.08
|
0.25
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.10
--
(Short term borrowings / Net worth)
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
0.10
|
0.12
|
0.10
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.91
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
0.91
|
3.36
|
2.86
|
4.77
|
3.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
0.87
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
0.87
|
3.17
|
2.74
|
4.62
|
3.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
--
|
--
|
--
|
-1.06
|
-6.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
11.11
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
11.11
|
10.55
|
1.91
|
16.88
|
31.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.25
--
Sales / Average Total Assets
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
0.25
|
0.26
|
0.74
|
0.99
|
0.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
51.23
--
Average Debtors / Sales * 365
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
51.23
|
32.87
|
45.40
|
59.02
|
60.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
73.54
--
Average Inventory / Sales * 365
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
73.54
|
58.13
|
21.73
|
27.46
|
83.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
328.02
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
328.02
|
169.26
|
65.65
|
43.16
|
116.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-203.26
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-203.26
|
-78.26
|
1.48
|
43.32
|
27.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-0.03
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-0.03
|
-1.65
|
-0.08
|
-0.08
|
-0.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.14
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
1.14
|
1.26
|
0.17
|
0.05
|
0.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.05
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Applied DNA Sciences (APDN)
|
-0.05
|
-0.44
|
0.53
|
1.15
|
0.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|